Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus

Comprehensive Therapy

Volumn 31, Issue 2, 2005, Pages 106-112

  Szoke, Ervin ^a   Gerich, John E ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; FATTY ACID; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; MEGLITINIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; RESISTIN; ROSIGLITAZONE; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; BODY FAT; BODY MASS; DIABETOGENESIS; DRUG EFFECT; FOOD INTAKE; GENE EXPRESSION; GENE MUTATION; GENE REPLICATION; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIPID DIET; METABOLIC REGULATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIFE STYLE; OBESITY;

EID: 26244463170     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1385/COMP:31:2:106     Document Type: Article

References (89)

1. National diabetes fact sheet: General information and national estimates on diabetes in the United States. Centers for Disease Control and Prevention 2003. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Washington, DC.
2. Harris M, Flegal K, Cowie C, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-524.
3. Himsworth H, Kerr R. Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci 1939;4:119-152.
4. Byrne M, Sturgis J, Sobel R, Polonsky K. Elevated plasma glucose 2h postchallenge predicts defects in B-cell function. Am J Physiol 1996;270:E572-E579.
5. Eriksson J, Franssila-Kallunki A, Ekstand A, et al. Early metabolic defects in persons at increased risk for noninsulin-dependent diabetes mellitus. N Engl J Med 1989;321:337-343.
6. Weyer C, Tataranni PA, Bogardus C, Pratley R. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2000;24:89-94.
7. Matthews D, Cull C, Stratton I, Holman R, Turner R. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 1998;15:297-303.
8. DeFronzo R. The triumvirate: B-cell, muscle, and liver: a collusion responsible for NIDDM. Diabetes 1988;37:667-687.
9. DeFronzo R, Bonadonna R, Ferrannini E. Pathogenesis of NIDDM. In: International Textbook of Diabetes Mellitus. (Alberti K, Zimmet P, DeFronzo R, eds.). Wiley, New York, 1997, 635-712.
10. Olefsky J. Diabetes Mellitus (Type II): Etiology and pathogenesis. In: Endocrinology. (DeGroot L, Besser M, Burger H, et al., eds.). W. B. Saunders, Philadelphia, 1995,1436-1463.
11. Gerich J. Is insulin resistance the principal cause of type 2 diabetes? Diabetes, Obesity and Metabolism 1999;1:257-263.
12. Van Haeften T, Pimenta W, Mitrakou A, et al. Relative contributions of b-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism 2000;49:1318-1325.
13. Lillioja S, Mott D, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 1993;329:1988-1992.
14. Lillioja S, Mott D, Howard B, et al. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988;318:1217-1225.
15. Martin B, Warram J, Krolewski A, Bergman R, Soeldner J, Kahn C. Role of glucose and insulin resistance in development of type II diabetes mellitus: results of a 25-year follow-up study. Lancet 1992;340:925-929.
16. Gulli G, Ferrannini E, Stern M, Haffner S, DeFronzo R. The metabolic profile of NIDDM is fully established in glucose- tolerant offspring of two Mexican-American NIDDM parents. Diabetes 1992;41:1575-1586.
17. Warram J, Martin B, Krolewski A, Soeldener S, Kahn C. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Int Med 1990;113:909-915.
18. Boden G, Chen X, Polansky M. Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes. Diabetes 1999;48:2182-2188.
19. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998;19(4):477-490.
20. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106(4):473-481.
21. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-2497.
22. Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1999;1 Suppl 1:S1-S7.
23. Reaven GM. Insulin resistance: a chicken that has come to roost. Ann NY Acad Sci 1999;892:45-57.
24. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287(3):356-359.
25. Familiar Medical Quotations. Little, Brown, Boston, 1968.
26. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000;11(9):351-356.
27. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 2000;23(4):465-471.
28. Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000;108 Suppl 6a:9S-14S.
29. Banerji M, Chaiken R, Gordon D, Kral J, Lebovitz H. Does intraabdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive? Diabetes 1995;44:141-146.
30. Carey D, Jenkins A, Campbell L, Freund J, Chisholm D. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996;45:633-638.
31. Bak J, Moller N, Schmitz O, Saaek A, Pedersen O. In vivo action and muscle glycogen synthase activity in type II (noninsulin dependent) diabetes mellitus: effects of diet treatment. Diabetologia 1992;35:777-784.
32. Beck-Nielsen H, Pedersen O, Lindskov H. Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year. Acta Endocrinol (Copenh) 1979;90:103-112.
33. Freidenberg G, Reichart D, Olefsky J, Henry R. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus: effect of weight loss. J Clin Invest 1988;82:1398-1406.
34. Long S, O'Brien K, MacDonald K Jr, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care 1994;17:372-375.
35. Pan X-R, Li G-W, Hu Y-H, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-544.
36. Knowler W, Barrett-Connor E, Fowler S, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
37. Tuomilehto J, Lindström J, Eriksson J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.
38. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003;238(4):467-484.
39. Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians 1999:111(3):241-248.
40. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51(1):7-18.
41. Steppan C, Bailey S, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
42. McTernan PG, Fisher FM, Valsamakis G, et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003;88(12):6098-6106.
43. Wang H, Chu WS, Hemphill C, Elbein SC. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002;87(6):2520-2524.
44. Engert JC, Vohl MC, Williams SM, et al. 5′ flanking variants of resistin are associated with obesity. Diabetes 2002;51(5):1629-1634.
45. Sentinelli F, Romeo S, Arca M, et al. Human resistin gene, obesity, and type 2 diabetes: mutation analysis and population study. Diabetes 2002;51(3):860-862.
46. Osawa H, Onuma H, Murakami A, et al. Systematic search for single nucleotide polymorphisms in the resistin gene: the absence of evidence for the association of three identified single nucleotide polymorphisms with Japanese type 2 diabetes. Diabetes 2002;51(3):863-866.
47. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24(1):29-33.
48. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148(3):293-300.
49. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004;53 Suppl 1:S143-S151.
50. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7(8):941-946.
51. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001;98(4):2005-2010.
52. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50(9):2094-2099.
53. Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 2002;440(2-3):213-221.
54. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002;105(23):2696-2698.
55. Hotamisligil G, Shargill N, Spiegelman B. Adipose expression of tumor necrosis factor a: direct role in obesity-linked resistance. Science 1993;259:87-91.
56. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95(5):2409-2415.
57. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289(14):1799-1804.
58. Bruun JM, Pedersen SB, Richelsen B. Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab 2001;86(3):1267-1273.
59. Straczkowski M, Dzienis-Straczkowska S, Stepien A, Kowalska I, Szelachowska M, Kinalska I. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab 2002;87(10):4602-4606.
60. Nyholm B, Mengel A, Nielsen S, Moller N, Schmitz O. The insulin resistance of relatives of type 2 diabetic subjects is significantly related to a reduced VO2 max. Diabetologia 37, A28 1994.
61. Swinburn B. Effects of dietery lipid on insulin action. Clinical studies. Ann NY Acad Sci 1993;683:102-109.
62. Pandit M, Burke J, Gustafson A, Minocha A, Peiris A. Drug-induced disorders of glucose tolerance. Ann Int Med 1993;118:529-539.
63. Yki-Järvinen H. Glucose toxicity. Endocr Rev 1992;13:415-431.
64. Stern MP. Strategies and prospects for finding insulin resistance genes. J Clin Invest 2000;106(3):323-327.
65. Vaag A. On the pathophysiology of late onset non-insulin dependent diabetes mellitus. Current controversies and new insights. Dan Med Bull 1999;46(3):197-234.
66. Kahn CR, Bruning JC, Michael MD, Kulkarni RN. Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes mellitus. J Pediatr Endocrinol Metab 2000;13 Suppl 6:1377-1384.
67. McIntyre EA, Walker M. Genetics of type 2 diabetes and insulin resistance: knowledge from human studies. Clin Endocrinol (Oxf) 2002;57(3):303-311.
68. Gerich J. Role of insulin resistance in the pathogenesis of type 2 (noninsulin-dependent) diabetes mellitus. Bailliere's Clinical Endocrinology and Metabolism 1988;2:307-326.
69. Burks DJ, White MF. IRS proteins and beta-cell function. Diabetes 2001;50 Suppl 1:S140-S145.
70. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000;106(3):329-333.
71. Kahn S. The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000;108(Suppl 6A):2S-8S.
72. Porte D. β-cells in type II diabetes mellitus. Diabetes 1991;40:166-180.
73. Karam J, Forsham P. Pancreatic hormones and diabetes mellitus. In: Basic and Clinical Endocrinology. (Greenspan F, Baxter J, eds.). Appleton & Lange, Norwalk, CT, 1994,571-634.
74. Gin H, Rigalleau V. Post-prandial hyperglycemia. post prandial hyperglycemia and diabetes. Diabetes Metab 2000;26(4):265-272.
75. Pigon J, Giacca A, Ostenson C-G, Lam L, Vranic M, Efendic S. Normal hepatic insulin sensitivity in lean mild noninsulin-dependent diabetic patients. J Clin Endocrinol Metab 1996;81:3702-3708.
76. Polonsky KS. Evolution of beta-cell dysfunction in impaired glucose tolerance and diabetes. Exp Clin Endocrinol Diabetes 1999;107 Suppl 4:S124-S127.
77. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52(1):102-110.
78. Guiot Y, Sempoux C, Moulin P, Rahier J. No decrease of the beta-cell mass in type 2 diabetic patients. Diabetes 2001;50(Suppl 1):S188.
79. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 2002;45(1):85-96.
80. Deng S, Vatamaniuk M, Huang X, et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004;53(3):624-632.
81. Vague P, Moulin J-P. The defective glucose sensitivity of the B cell in noninsulin dependent diabetes: improvement after twenty hours of normoglycemia. Metabolism 1982;31:139-142.
82. Rossetti L, Giaccari A, DeFronzo R. Glucose Toxicity. Diabetes Care 1990;13:610-630.
83. Unger R. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995;44:863-870.
84. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998;95(5):2498-2502.
85. Kahn S. The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047-4058.
86. Levy J, Atkinson A, Bell P, McCance D, Hadden D. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabetic Med 1998;15:290-296.
87. Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-372.
88. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27(7):1535-1540.
89. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management - 2000 update. Endocr Pract 2000;6(1):43-84.